The looming prospect of a disorderly Brexit at the end of March is spreading fear within the pharmaceuticals sector and life sciences industry, where the development of drugs and other products depends heavily on the political and regulatory conditions of a country and often require planning years in advance, while the provision of drugs to patients often requires tight timetables.
A disorderly Brexit became more likely Jan. 15 when the UK parliament overwhelmingly rejected UK Prime Minister Theresa May's proposed...








